BPOC, a pure-play healthcare investor, has formed a new partnership with experienced pharmaceutical executive, Mark Scullion, to build a clinical research site platform serving the pharmaceutical market.
Scullion has spent more than 15 years in the clinical research industry and brings a unique understanding of the site selection process and value needs of pharmaceutical sponsors. He was most recently the Global Head of Trial Monitoring for Novartis AG, and also previously held leadership roles at Syneos Health and IQVIA, where he developed novel approaches to clinical trial design and execution. At Novartis Scullion led a group of clinical professionals delivering over 300 clinical studies in partnership with 14,000 investigative sites across the world.
BPOC will work with Scullion to build a site network through acquisition and organic growth leveraging a centralised platform that will solve critical pain points for pharmaceutical sponsors. This effort marks BPOC’s third partnership in the pharmaceutical services space in the last year and is consistent with the firm’s thesis-driven approach to investing. In December 2021, BPOC made a strategic investment in Network Partners, a leading provider of consulting services to medical device and pharmaceutical companies, and in August 2022, the firm made an investment in Praxis Packaging Solutions, a provider of primary and secondary contract packaging services for over-the-counter and prescription pharmaceutical, medical device, animal health and health & beauty industries.
BPOC and Scullion believe there is ample opportunity to create value in the space through consolidation of sites and the formation of a robust site network that creates a more commercially oriented business with tighter operational controls, greater access to patients and increased speed to trial – leading to greater reliability and lower costs for trial sponsors and CROs.
